Stockbroking | Wealth Management | Corporate Advice

x

Resizing text on the web

To increase or decrease the magnification of a web page, press Ctrl and '+' (plus) to zoom in or Ctrl and '-' (minus) to zoom out. To return the page to its original size, press Ctrl + 0.

You can also scroll the mouse wheel up and down while holding Ctrl to increase/decrease zoom level.

Nufarm plunges after Monsanto court ruling

A Californian court finding that a Monsanto weedkiller caused cancer in a school groundskeeper sent shares in the Australian maker of a similar product, Nufarm, tumbling to a more than two-year low on Monday.

A California jury on Friday found Monsanto liable in a lawsuit filed by a man who alleged the company's glyphosate-based weed-killers caused his cancer and ordered the firm to pay $US289 million ($396m) in damages.

Macquarie Bank analysts estimate Nufarm earns about a fifth of its revenue from products containing glyphosate, the world's most widely-used herbicide.

"There is longer term regulatory risk (regarding) this, if (we) do see a change of regulatory stance over time," Macquarie analysts wrote in a note published on Monday.

Concerns about glyphosate drove down Nufarm shares almost 17 per cent in early trade to their lowest since February 2016.

The stock has already been battered after the company issued a profit warning in July citing lower demand for its crop-protection products after dry weather in Australia.

The firm, however, sought to allay investor worries, saying in a statement on the ASX that it does not expect glyphosate-related issues that have arisen over the past week to "have any impact on Nufarm's business".

"The product has a 40-year history of safe use and continues to be an important tool for farmers. Nufarm will continue to work with regulatory authorities around the globe to maintain its glyphosate registrations," the statement said.

Monsanto, owned by Germany's Bayer AG, also denies that glyphosate causes cancer and says decades of scientific studies have shown the chemical to be safe for human use. It is appealing the California jury's verdict.

The US Environmental Protection Agency in September 2017 concluded a decades-long assessment of glyphosate risks and found the chemical not likely carcinogenic to humans.

But the World Health Organisation's cancer arm had in 2015 classified glyphosate as "probably carcinogenic to humans" and earlier this month Brazil suspended the use of the chemical for 30 days while it weighs health concerns.

In 2016, The Weekly Times quoted Nufarm Managing Director Greg Hunt saying the firm had "worked very hard to reduce its reliance on glyphosate" to 20 per cent from 50 per cent.

Nufarm shares were down $1.08, or 14.3 per cent, to $6.46 at 1424 AEST.

Austrlaian Associated PressBack to Breaking News

Market Indices